AMRIF has filed a patent in using Alkaline Phosphatase to treat arthritis, based on promising data from animal model.
Arthritis is a common health problem, affecting about 20% adults. It is also the No. 1 cause of disability in the US.
Rheumatoid arthritis (RA) is the third most common type of arthritis, affecting about 1% population worldwide. The specific cause for RA is not clear, and there is no cure for the disease. Current treatment focus on slowing the progression of joint damage. Despite biologics and new class oral drugs, there is still high demand for more efficacious and better tolerated drugs in RA.
How does RESCAP® treat arthritis?
Extracellular ATP is a key signaling molecule in inflammatory processes. It triggers immune cells to release the pro-inflammatory signals such as TNFa, IL6 and IL8. RESCAP® breaks down ATP, prevents the pro-inflammatory signals to be formed, consequently prevents inflammation and tissue damage.
It has been confirmed in preclinical and clinical studies that RESCAP® reduce pro-inflammatory markers TNFa, IL6 and IL8. An animal study (RA model) shows that RESCAP® reduces knee swelling and infiltration of activated white blood cells in joints.
human recombinant RESCAP® for Arthritis
AMRIF’s human recomninant hRESCAP is unqiue for its long half life time of 6 days. It has favourable pharmacokinetics, providing bi-weekly subcutaneous dosing regime and wide therapeutic window.
hRESCAP is currently in a Phase lb study in RA.
Idzko et al. Nucleotide signalling during inflammation. Nature 2014; 509, 310-317.
Chandrupatla et al. Prophylactic and therapeutic activity of alkaline phosphatase in arthritic rats: single-agent effects of alkaline phosphatase and synergistic effects in combination with methotrexate. Transl Res. 2018 Sep;199:24-38. doi: 10.1016/j.trsl.2018.04.001. Epub 2018 May 17.